Matti Poutanen
 PhD


matpou@utu.fi

+358 29 450 2632

+358 50 366 0140

Kiinamyllynkatu 10

Turku

Työhuone: C507


ORCID-tunniste: https://orcid.org/000-0002-8953-1734

http://www.tcdm.fi/research/poutanen-matti/

Asiantuntijuusalueet
geenimuunnellut eläimet, steroidi hormoni, endometrioosi, hormonaalinen syöpä

Biografia

EDUCATIONAL
TRAINING



1987, M.Sc., Department of Biochemistry, University of
Oulu, Finland



1993, Ph.D., Department of Clinical Chemistry,
University of Oulu, Finland         



1997, Title of Docent
(Adjunct professor); Biochemical Endocrinology, University of Oulu, Finland   




CURRENT
POSITIONS



Professor, Department of Physiology,
University of Turku, and Director of Turku Center for Disease Modeling,
University of Turku, Finland



Senior Scientist
lecturer, Institute of Medicine, The Sahlgrenska Academy, Gothenburg
University, Gothenburg, Sweden

MAJOR GRANTS:
Academy
of Finland, The Finnish Cancer Organisations, Sigrid Juselius Foundation, Novo
Foundation, Vetenskaps Rådet, Business Finland and Industry

SUPERVISION OF STUDENTS: 30 PhD students supervised, 6 in training.



SCIENTIFIC
AND SOCIETAL IMPACT OFD THE WORK



Research
is mainly focused on sex steroid synthesis and action, with total number of
citation 6270 (Web of Science, April 2018); number of citations in 2017: ~400;
average citations per article: 26.8; h-index: 46; 182 original peer-reviewed
publications; 5 publications in high-impact journals (I.F. ≥ 10): J. Clin. Invest. 2x (I.F. 13), Cell Metab.(I.F. 17), Nat. Med. (I.F.
28), Gut (I.F. 14)



 Co-founder, Forendo
Pharma ltd (www.forendo.com) focusing on hormonal therapies for endometriosis
and male hypogonadism. The company has closed its investment rounds with the
leading Nordic start-up investors Karolinska Development AB, Novo Seeds and
Finnvera. 



Tutkimus
Our research group has been internationally in a key position in
providing evidence for the concept where the ligand concentration available for
steroid hormone receptor binding is markedly regulated by the target tissue
metabolism, termed intracrine steroid
hormone action. The concept has proven to be essential for the growth and
progression of both prostate and breast cancer. We, furthermore, have shown
this concept to be valid also in premenopausal women, eg. in the endometriosis,
and other medically relevant implications are expected to rise in the near
future.

Opetus

Teaching experience in, endocrinology, developmental biology, hormonal cancer, GM mice and animal models and in vivo imaging



Julkaisut
  
null
  
null
  
17/20
  
null
  
null
  

Last updated on